Our Pipeline

Focused on making an impact in the lives of people living with cancer

Cyclacel’s pipeline of medicines aims to provide safe and effective anticancer treatment options to patients combined with the convenience of oral administration. We have retained worldwide rights for all of our prescription candidates.

*Phase 2 in planning. AML, acute myeloid leukemia; CDK, cyclin-dependent kinase; CLL, chronic lymphocytic leukemia; IV, intravenous; MDS, myelodysplastic syndrome; MOA, mechanism of action; PLK, polo-like kinase; PoC, proof of concept. 065-102 streamlined multicohort oral study to PoC in leukemias/MDS Streamlined multicohort oral study to PoC in solid tumors 065-101 streamlined multicohort oral study to PoC in solid tumors Rx Candidate & MOA Phase 1 Phase 1- 2 Phase 3 Fadraciclib Oral CDK2 and CDK9 Plogosertib Oral PLK1 065-01 parts 1, 2 IV part 3 in oral solid tumors 065-02 IV + venetoclax in CLL 065-03 IV + venetocloax in AML/MDS

Our Clinical Trials

icon - Fadraciclib

Fadraciclib is a highly selective inhibitor of CDK2 and CDK9 currently being evaluated in midstage clinical trials in both patients with solid cancers and hematologic malignancies.

Learn More About Fadraciclib
icon - CYC140

Plogosertib is a highly selective PLK-centric inhibitor currently in Phase 1 studies. Midstage clinical trials in both patients with solid cancers and hematologic malignancies are being planned.

Learn More About Plogosertib

Cyclacel’s candidates are experimental drugs under clinical investigation. They are not approved for human use at this time.

icon - Sapacitabine

Sapacitabine (CYC682) is an orally available nucleoside analogue with a unique DDR mechanism.

Learn More About Sapacitabine

Interested in Learning More About Cyclacel?

Contact Us
woman and man on computer

Paul McBarron

Executive Vice President, Chief Financial Officer & Chief Operating Officer​

Mr. McBarron has served as a director of the Company since March 2006. Mr. McBarron joined Cyclacel in January 2002 and has over 30 years of experience with pharmaceutical and biotechnology companies. He has served as a financial executive at Sterling Drug, Sanofi-Winthrop and SmithKline Beecham and, from 1996 to 2001, as a senior member of the finance team at Shire Pharmaceuticals plc, where he held the positions of Director of Corporate Finance and Group Financial Controller. He joined Shire when it was an emerging public company. He qualified as a chartered accountant with Ernst & Young and served on the Scottish Lifesciences Association Board.